The regulatory edge: How i-GENTIC AI is redefining life sciences compliance

Bringing a product to market in the life sciences has never been more complex or more consequential. Regulatory pathways are demanding. FDA scrutiny is intensifying. And the cost of a failed submission, a missed post-market signal, or an unresolved CAPA is not just financial. It is competitive.

The industry’s most forward-thinking leaders in MedTech, pharma, and biotech are not waiting to find out what those costs look like. They are turning to i-GENTIC AI.

One platform. Every pathway.

Whether your product is navigating a 510(k), forging new ground through De Novo, advancing through a PMA, or managing the complexity of an NDA, BLA, or IND submission, i-GENTIC’s GENIE platform operates as a continuous, intelligent layer of regulatory governance, reasoning across your documentation in real time, not after the fact.

Traditional compliance systems act like a basic checklist, confirming a document exists but unable to tell you whether the data still makes sense after months of design changes and internal reviews. GENIE is fundamentally different. It traces logic across your entire submission architecture, including study data, risk analyses, clinical evidence, labeling, manufacturing controls, and intended use, surfacing cross-document inconsistencies before FDA reviewers do.

For 510(k) and De Novo filers, that means arriving at submission with a coherent, defensible narrative. For PMA sponsors and BLA applicants managing thousands of pages of clinical and manufacturing documentation, it means enterprise-scale consistency that no human team can replicate alone. For emerging biotech companies navigating IND filings and novel therapeutic pathways, it means a dynamic reasoning engine that adapts to your evidence structure at every stage of development.

Customers have improved first-time submission success rates by up to 97% and reduced approval timelines by an average of six weeks.

In a market where speed to clearance and approval is a direct competitive advantage, that margin defines winners.

Compliance that does not stop at approval

Regulatory responsibility intensifies after approval. Post-market surveillance obligations, pharmacovigilance requirements, evolving FDA guidance, and the ever-present risk of data drift demand continuous vigilance. Yet most organizations still rely on manual tracking, reactive CAPA workflows, and siloed quality systems that leave them perpetually exposed.

i-GENTIC’s agents monitor real-world performance and safety signals continuously, correlating post-market data against approved specifications, triggering CAPA workflows automatically when deviations emerge, and adapting to new regulatory requirements without manual intervention. GENIE reads regulatory updates, converts them into actionable enforcement logic, and deploys updated agents in response, so your compliance posture evolves as FDA expectations do.

Built for leaders who cannot afford to be reactive

“Organisations should not have to choose between speed and safety. With GENIE, they can have both,” says Zahra Timsah, Co-founder and CEO, i-GENTIC AI

For regulatory affairs leaders, quality officers, and C-suite executives across MedTech, pharma, and biotech who understand that governance is not overhead but competitive infrastructure, i-GENTIC AI delivers the platform to prove it.

Visit igenticai.com to request an executive briefing.